Searcher - Research groups
Asset Publisher

Tuberculosis

Tuberculosis

 

The current WHO strategy (END-TB) aims to reduce TB incidence and TB mortality by 90 and 95% respectively by 2035 (as compared to 2015). This acceleration in TB control efforts will not be possible without an improved TB vaccine. In addition to the development and implementation of an effective vaccine, the development of new point of care tests, shorter treatment regimens for drug susceptible and drug resistant TB, and improved access to testing, are key elements which will pave the road to achieving global control / elimination targets.

The mycobacterial infections caused by Non-Tuberculous Mycobacteria (NTM) are experimenting an increase in incidence worldwide, especially in patients with chronic pulmonary disease as COPD or bronchiectasis, being cause of morbidity and continuous treatment during years, without a clear perspective of curation.

Who do we colaborate

Main research lines

  • Determine disease burden in vulnerable populations (children, HIV-infected, pregnant)
  • Assess the impact of innovative strategies for the active search for cases based on spatial parameters, population density and microbial load in index cases
  • Evaluate new diagnostic tools in contexts of high prevalence of TB and HIV
  • Evaluate new biomarkers for the diagnosis and treatment of TB

Our Team

SToolNIH

Quantifiable stool-based TB PCR to Improve Diagnostics and Treatment Monitoring

TB-RECONNECT

Reconnecting Transmission to Global Tuberculosis Control by Mapping Pathogen Transmission Events to Host Infection Status

CAPTB

Close the Gap, Increase Access, Provide Adequate Therapy

Stool4TB

Evaluating a new stool based qPCR for diagnosis of tuberculosis in children and people living with HIV

2G Color Plates

2nd Generation Color Agar Plates to Diagnose MDR-Tuberculosis: a Prospective Pilot Study

PreFIT

Predicting the Future: Incipient Tuberculosis

WHIP3TB

Evaluation of the effect of weekly high dose rifapentine and isoniazid (3HP) vs periodic 3HP vs 6H for preventing TB among HIV-positive individuals